Head and Neck Squamous Cell Carcinomas: Biomarkers and Cellular Mechanisms towards a Precision Therapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2521

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Head & Neck Oncology & Surgery Otorhinolaryngology, Antoni van Leeuwenhoek, Nederlands Kanker Instituut, Amsterdam, The Netherlands
2. Department of Otorhinolaryngology, Head & Neck Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands
Interests: head and neck neoplasms; laryngeal neoplasms; salivary gland tumors; digital pathology; laryngology; cancer immunology; biostatistics; melanoma; cutaneous oncology; immunotherapy

Special Issue Information

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) is the seventh most prevalent cancer worldwide, characterized by a relatively worse prognosis and the adverse impact of treatments on patients' quality of life. Apart from surgery and radiotherapy, there are only a few available systemic treatments, primarily involving platinum-based chemotherapy or cetuximab. Immunotherapy, a novel therapeutic approach, is currently limited to palliative care for cases of recurrent, unresectable, or metastatic disease. Consequently, the exploration of new biomarkers or potentially targetable mechanisms holds significant importance. The identification of subgroups of patients that could benefit from a de-intensified treatment regimen is also of paramount importance, aimed at a precision therapy reducing the tremendous toxicity of the current treatment modalities for HNSCC.

This Special Issue of Cells is focused on the latest advances and future trends in cellular, molecular, and biomarker research in the field of head and neck cancer. This Special Issue will include both original research articles as well as up-to-date review papers.

Dr. Francesco Missale
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • biomarkers
  • prognosis
  • precision therapy
  • immunotherapy
  • translational research
  • immune contexture

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1000 KiB  
Review
Potential Transcript-Based Biomarkers Predicting Clinical Outcomes of HPV-Positive Head and Neck Squamous Cell Carcinoma Patients
by J. Omar Muñoz-Bello, Sandra L. Romero-Córdoba, J. Noé García-Chávez, Claudia González-Espinosa, Elizabeth Langley and Marcela Lizano
Cells 2024, 13(13), 1107; https://doi.org/10.3390/cells13131107 - 26 Jun 2024
Cited by 1 | Viewed by 2216
Abstract
Human papillomavirus (HPV)-positive Head and Neck Squamous Cell Carcinomas (HNSCC) comprise a particular cancer entity traditionally associated with better clinical outcomes. Around 25% of HNSCC are HPV positive, HPV16 being the most prevalent type. Nevertheless, close to 30% of the HPV-positive patients have [...] Read more.
Human papillomavirus (HPV)-positive Head and Neck Squamous Cell Carcinomas (HNSCC) comprise a particular cancer entity traditionally associated with better clinical outcomes. Around 25% of HNSCC are HPV positive, HPV16 being the most prevalent type. Nevertheless, close to 30% of the HPV-positive patients have an unfavorable prognosis, revealing that this type of tumor exhibits great heterogeneity leading to different clinical behaviors. Efforts have been made to identify RNA molecules with prognostic value associated with the clinical outcome of patients with HPV-positive HNSCC, with the aim of identifying patients at high risk of metastasis, disease recurrence, and poor survival, who would require closer clinical follow-up and timely intervention. Moreover, the molecular identification of those HPV-positive HNSCC patients with good prognosis will allow the implementation of de-escalating therapeutic strategies, aiming to reduce side effects, resulting in a better quality of life. This review compiles a series of recent studies addressing different methodological and conceptual approaches aimed at searching for potential gene expression-based biomarkers associated with the prognosis of patients with HPV-positive HNSCC. Full article
Show Figures

Figure 1

Back to TopTop